Evidence map›Paper›PMID 38480557›Full record

ArticlePsychopharmacology2024

Long-term disruption of tissue levels of glutamate and glutamatergic neurotransmission neuromodulators, taurine and kynurenic acid induced by amphetamine.

Ewa Taracha, Magdalena Czarna, Danuta Turzyńska, Alicja Sobolewska, Piotr Maciejak

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ewa TarachaDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, 9 Sobieskiego St, Warsaw, 02-957, Poland. taracha@ipin.edu.pl.ORCID http://orcid.org/0000-0002-8059-4966
Magdalena CzarnaDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, 9 Sobieskiego St, Warsaw, 02-957, Poland.
Danuta TurzyńskaDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, 9 Sobieskiego St, Warsaw, 02-957, Poland.
Alicja SobolewskaDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, 9 Sobieskiego St, Warsaw, 02-957, Poland.
Piotr MaciejakDepartment of Experimental and Clinical Neuroscience, Institute of Psychiatry and Neurology, 9 Sobieskiego St, Warsaw, 02-957, Poland.
Institute of Psychiatry and Neurology · PLMedical University of Warsaw · PL

Funding

Narodowym Centrum Nauki UMO- 2015/19/B/NZ7/03610
6 · The paper itself

Abstract

rationaleChronic amphetamine (AMPH) use leading to addiction results in adaptive changes within the central nervous system that persist well beyond the drug's elimination from the body and can precipitate relapse. Notably, alterations in glutamatergic neurotransmission play a crucial role in drug-associated behaviours.

objectivesThis study aimed to identify changes induced by amphetamine in glutamate levels and the neuromodulators of glutamatergic neurotransmission (taurine and kynurenic acid) observable after 14 and 28 days of abstinence in key brain regions implicated in addiction: the cortex (Cx), nucleus accumbens (Acb), and dorsolateral striatum (CPu-L).

methodsThe rats were administered 12 doses of amphetamine (AMPH) intraperitoneally (i.p.) at 1.5 mg/kg. The behavioural response was evaluated through ultrasonic vocalizations (USV). High-performance liquid chromatography (HPLC) was used to measure the levels of glutamate, taurine, and kynurenic acid in the Cx, Acb, and CPu-L after 14 and 28 days of abstinence.

resultsAMPH administration led to sensitisation towards AMPH's rewarding effects, as evidenced by changes in USV. There was a noticeable decrease in kynurenic acid levels and an increase in both taurine and glutamate in the CPu-L, along with an increase in glutamate levels in the Cx, 28 days following the final AMPH injection.

conclusionsThe most significant changes in the tissue levels of glutamate, taurine, and kynurenic acid were seen in the CPu-L 28 days after the last dose of AMPH. The emergence of these changes exclusively after 28 days suggests that the processes initiated by AMPH use and subsequent abstinence take time to become apparent and may be enduring. This could contribute to the incubation of craving and the risk of relapse. Developing pharmacological strategies to counteract the reduction in kynurenic acid induced by psychostimulants may provide new avenues for therapy development.

Indexed as

AmphetamineCentral Nervous System StimulantsGlutamic AcidKynurenic AcidSynaptic TransmissionTaurineAmphetamine-Related DisordersAnimalsCerebral CortexMaleNucleus AccumbensRatsRats, WistarRewardTime FactorsAmphetamineCentral Nervous System StimulantsGlutamic AcidKynurenic AcidTaurineAbstinenceAddictionAmphetamineGlutamateKynurenic acidNeuromodulatorsNeuroprotectionTaurineUltrasonic vocalizationWithdrawal

Identifiers

PMID38480557
OpenAlexW4392816350

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.